Whole leukemia cell vaccines: Past progress and future directions
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ji, Young Sok | - |
dc.contributor.author | Park, Seong Kyu | - |
dc.contributor.author | Ryu, Seongho | - |
dc.date.accessioned | 2021-08-11T08:36:05Z | - |
dc.date.available | 2021-08-11T08:36:05Z | - |
dc.date.issued | 2020-05-08 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.issn | 1358-8745 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2827 | - |
dc.description.abstract | It has long been recognized that allogeneic hematopoietic stem cell transplantation can reduce the risk of leukemia relapse by inducing the graft-versus-leukemia effect. However, allogeneic stem cell transplantation is also known to be able to cause graft-versus-host disease, which can cause considerable morbidity and even mortality in patients receiving allogeneic hematopoietic stem cell transplantation. Therefore, to elicit leukemia-specific immune responses without alloimmune reaction, the possibilities of active immunotherapy methods such as leukemia vaccines have been studied for decades. Among various types of leukemia vaccines, whole leukemia cell vaccines are known to be able to induce immune responses against multiple unknown antigens without the need for adoptive transfer of dendritic cells. In this review, we will discuss the past progress of whole leukemia cell vaccines, with a focus on strategies to enhance their immunogenicity. We will also present the future directions of whole leukemia cell vaccines along with addressing newly emerging concepts, such as immunogenic cell death and necroptosis. We will not discuss in detail other factors that can reduce the therapeutic efficacy of whole leukemia cell vaccines such as various immunosuppressive mechanisms of leukemia. (C) 2020 The Author(s). Published by Elsevier Ltd. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Whole leukemia cell vaccines: Past progress and future directions | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1016/j.vaccine.2020.03.042 | - |
dc.identifier.scopusid | 2-s2.0-85082977838 | - |
dc.identifier.wosid | 000528840000001 | - |
dc.identifier.bibliographicCitation | Vaccine, v.38, no.22, pp 3811 - 3820 | - |
dc.citation.title | Vaccine | - |
dc.citation.volume | 38 | - |
dc.citation.number | 22 | - |
dc.citation.startPage | 3811 | - |
dc.citation.endPage | 3820 | - |
dc.type.docType | Review | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | ACUTE MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | COLONY-STIMULATING FACTOR | - |
dc.subject.keywordPlus | ACUTE LYMPHOBLASTIC-LEUKEMIA | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | COSTIMULATORY MOLECULES | - |
dc.subject.keywordPlus | IMMUNE-RESPONSE | - |
dc.subject.keywordPlus | T-CELLS | - |
dc.subject.keywordPlus | B-CELLS | - |
dc.subject.keywordPlus | GM-CSF | - |
dc.subject.keywordPlus | CALRETICULIN EXPOSURE | - |
dc.subject.keywordAuthor | Whole leukemia cell vaccines: Past progress and future directions | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.